Navigating the neurological frontier – 2024 and beyond
Posted: 29 January 2024 | Drug Target Review | No comments yet
Listen to this podcast where we step into the new year and explore research insights and projections for the field in 2024 in neuroscience.
As we step into the new year, we explore research insights and projections for the field in 2024 in neuroscience.
In this episode titled: Navigating the neurological frontier – 2024 and beyond, we want to find out what are the most exciting recent advancements in neuroscience, setting the stage for the future.
This conversation features Dr Alessio Travaglia, Director, Translational Science at the Foundation for National Institutes of Health (FNIH), and Steve Hoffmann, Associate Vice President, Science Partnerships, Translational Science, and Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH).
Key learning points:
- How will emerging technologies like AI and neuroimaging influence brain study and understanding?
- How do you think the contribution of neuroscience will develop understanding of mental health disorders?
- Could you discuss the evolution of any technologies that you think will be popular in 2024?
This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About our speakers
Dr Alessio Travaglia
Director, Translational Science at the Foundation for National Institutes of Health (FNIH)
Dr Travaglia is a neuroscientist with more than 15 years of experience in basic and translational neuroscience in settings including academia, non-profit, management consulting, and venture philanthropy. He currently works as Director of Translational Science, Neuroscience. In this role, he leads the FNIH’s neuroscience programmes, facilitates the advancement and execution of innovative public-private partnerships, and collaborates with government, industry, academia, patient advocacy groups, and private sector organisations.
Steve Hoffmann
Associate Vice President, Science Partnerships, Translational Science, and Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH).
Hoffmann provides strategic planning, programmatic management, and research administration for a multi-faceted portfolio of established and emerging projects within the Biomarkers Consortium and Accelerating Medicines Partnership, including projects focused on neuroscience, rare diseases, organ toxicity, and infectious, autoimmune, and inflammatory diseases.
Steve has a broad background in the academic, government and industry sectors in the field of translational biomarkers, molecular immunology, and precision medicine. Prior to joining the FNIH, Steve worked as both a project and product manager, supporting protein diagnostics development at Meso Scale Discovery (MSD). Before MSD, Steve was a scientist in the Transplantation and Autoimmunity Branch of National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) and led research efforts utilising immune depletion and co-stimulatory blockage strategies for human renal and islet cell transplant trials. Steve holds a Master of Science in Pathology and Laboratory Medicine from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biochemistry and Biophysics from the University of Pittsburgh.
Related topics
Neurosciences
Related organisations
FNIH
Related people
Dr Alessio Travaglia (FNIH), Steve Hoffmann (FNIH)
